Company profile: Roivant
1.1 - Company Overview
Company description
- Provider of biopharmaceutical medicines and healthcare technologies, developing VTAMA (tapinarof) cream for plaque psoriasis and atopic dermatitis in adults and children 2+, Brepocitinib (TYK2/JAK1) for dermatomyositis and non-infectious uveitis, IMVT-1402 (FcRn inhibitor) for autoimmune diseases including Graves' disease, Namilumab for sarcoidosis, and Mosliciguat for pulmonary hypertension associated with interstitial lung disease.
Products and services
- VTAMA (Tapinarof) Cream: A topical therapy engineered for plaque psoriasis and atopic dermatitis, usable by adults and children as young as 2 years
- IMVT-1402: An FcRn inhibitor developed for autoimmune diseases such as Graves' disease, engineered to reduce circulating IgG levels
- Brepocitinib: A small-molecule drug targeting TYK2/JAK1, under development for treating dermatomyositis and non-infectious uveitis in patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Roivant
Questcor Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical treatments for serious, difficult-to-treat autoimmune and inflammatory disorders, focused on neurology and nephrology, and supporting research efforts in a variety of conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Questcor Pharmaceuticals company profile →
Aurex Labs
HQ: United States
Website
- Description: Provider of fully integrated pharmaceutical development and manufacturing services, including high-quality clinical supplies, tablets, and soft gelatin capsules. Maintains capabilities for manufacturing various dosage forms and quality control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aurex Labs company profile →
Gilead
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for critical diseases, discovering, developing, manufacturing and commercializing treatments across virology, oncology and inflammation. Portfolio includes Biktarvy and Descovy for HIV-1 (treatment and PrEP) and Epclusa for HCV, with efforts to transform viral diseases into manageable conditions and expand access to care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gilead company profile →
New Haven Pharmaceuticals
HQ: United States
Website
- Description: Provider of prescription pharmaceuticals utilizing drugs or GRAS active pharmaceutical ingredients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full New Haven Pharmaceuticals company profile →
Immunex
HQ: United States
Website
- Description: Provider of therapeutic products for cancer, infectious diseases, and autoimmune disorders. Develops, manufactures, and markets treatments including Enbrel for rheumatoid arthritis and Novantrone for acute nonlymphocytic leukemia and pain associated with prostate cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunex company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Roivant
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Roivant
2.2 - Growth funds investing in similar companies to Roivant
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Roivant
4.2 - Public trading comparable groups for Roivant
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →